CLEVELAND--(BUSINESS WIRE)--Ganeden Biotech, the largest seller of over-the-counter probiotic bacteria in the United States, today announced it will make available for license its patent related to the use of its probiotics to control bacterial infections associated with infant mortality, specifically, Sudden Infant Death Syndrome (SIDS).
